Trial
NCT02408016
Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI)
Condition
Advanced Pleural Malignant Mesothelioma
Intervention
Aldesleukin
Why stopped
Terminated due to loss of funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-09-13